Concepedia

Mary E. Hanson

ME

Statistics

Publications

32

Citations

1.2K

H-Index

21

Active since

1984

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Harvard University

St. Michael's Hospital

University of California, Los Angeles

The University of Texas MD Anderson Cancer Center

Mary E. Hanson is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, pharmacotherapy, and medicine.

ORCID

Publications per year

1984–2024

32

Publications

32

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence

Dale N. Gerding, Ciarán P. Kelly, Galia Rahav et al. · Clinical Infectious Diseases · 2018 · 206 citations · Full text

, , +16

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease

Lawrence A. Leiter, Harold Bays, Scott Conard et al. · The American Journal of Cardiology · 2008 · 87 citations

, , +15

Costs associated with outpatient, emergency room and inpatient care for migraine in the USA

Ralph P. Insinga, Daisy Ng‐Mak, Mary E. Hanson · Cephalalgia · 2011 · 87 citations · Full text

, , +17

Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).

Edward B. Garon, Natasha B. Leighl, Naiyer A. Rizvi et al. · Journal of Clinical Oncology · 2014 · 64 citations

, , +17

Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).

Naiyer A. Rizvi, Edward B. Garon, Amita Patnaik et al. · Journal of Clinical Oncology · 2014 · 62 citations

, , +17

1–5 of 32